Abstract: An exemplary semiconductor device can comprise (a) a substrate comprising a substrate dielectric structure between the substrate top side and the substrate bottom side, conductive pads at the substrate bottom side, and a substrate cavity through the substrate dielectric structure, (b) a base electronic component comprising inner short bumps; outer short bumps bounding a perimeter around the inner short bumps, and tall bumps between the outer short bumps and an edge of the base component top side, and (c) a mounted electronic component coupled to the inner short bumps of the base electronic component. The tall bumps of the base component can be coupled to the conductive pads of the substrate. The mounted electronic component can be located in the substrate cavity. The substrate bottom side can cover at least a portion of the outer short bumps of the base electronic component. Other examples and related methods are disclosed herein.

Abstract: The present disclosure is directed to a protein binding agent, or an antibody or an antigen-binding fragment thereof, which binds to a programmed death-1 (PD-1) protein. The present disclosure further provides a polynucleotide sequence encoding the protein binding agent, the antibody or the antigen-binding fragment thereof, a vector comprising the polynucleotide sequence, or a host cell comprising the vector. Also, the present disclosure provides a pharmaceutical composition or a kit, which comprises the protein binding agent, the antibody or the antigen-binding fragment thereof.

Abstract: An antibody that specifically binds to ErbB3 or an antigen-binding fragment thereof, and use thereof, are provided. The antibody that specifically binds to ErbB3 or an antigen-binding fragment thereof may be effectively used to prevent or treat a disease related to activation or overexpression of ErbB3 protein.

Abstract: An antibody that specifically binds to ErbB3 or an antigen-binding fragment thereof, and use thereof, are provided. The antibody that specifically binds to ErbB3 or an antigen-binding fragment thereof may be effectively used to prevent or treat a disease related to activation or overexpression of ErbB3 protein.

Abstract: The present invention relates to a VEGF polypeptide that binds to A?. The present invention also relates to a compound that sequesters A?. And conversely, the invention relates to a compound that sequesters VEGF. Thus, the present invention also relates to a method of screening for a compound that inhibits the binding of VEGF to A?, and thus relates to prevention and treatment of Alzheimer's Disease.

Abstract: The present invention relates to a VEGF polypeptide that binds to A?. The present invention also relates to a compound that sequesters A?. And conversely, the invention relates to a compound that sequesters VEGF. Thus, the present invention also relates to a method of screening for a compound that inhibits the binding of VEGF to A?, and thus relates to prevention and treatment of Alzheimer's Disease.

Abstract: Disclosed are novel peptides inhibitory of the activity of vascular endothelial growth factor (VEGF) and their use in the treatment of angiogenesis-related diseases, including cancer. A combinatorial library of peptides consisting of six amino acid residues were chemically synthesize and, from the library, specific amino acid residues for each amino acid position were screened by comparing their inhibitory activity against VEGF binding to the cell surface receptor. The novel peptide sequences thus obtained bind to VEGF and block the binding of VEGF to its receptors present on the surface of vascular endothelial cells, thereby inhibiting the hormonal activity of VEGF. The peptides inhibit the angiogenesis induced by VEGF and human cancer cells. Also, the peptides inhibit growth and metastasis of human cancer cells transplanted to mice. Thus, the peptides can be used to treat angiogenesis-related diseases, including cancer, diabetic retinopathy, rheumatoid arthritis, etc.